James L Gulley

James L Gulley

UNVERIFIED PROFILE

Are you James L Gulley?   Register this Author

Register author
James L Gulley

James L Gulley

Publications by authors named "James L Gulley"

Are you James L Gulley?   Register this Author

100Publications

2990Reads

12Profile Views

Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Oncologist 2019 Oct 10. Epub 2019 Oct 10.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0470DOI Listing
October 2019

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.

J Immunother Cancer 2019 Sep 5;7(1):240. Epub 2019 Sep 5.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0706-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729083PMC
September 2019

Perspectives on the clinical development of immunotherapy in prostate cancer.

Asian J Androl 2018 May-Jun;20(3):253-259

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/aja.aja_9_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952479PMC
June 2019

A Case of Anti-PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema.

Clin Genitourin Cancer 2019 Jun 14;17(3):e549-e552. Epub 2019 Feb 14.

Genitourinary Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.02.005DOI Listing
June 2019

Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.

BMC Cancer 2019 Jun 4;19(1):539. Epub 2019 Jun 4.

Dermatology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, 12N240C, Bethesda, MD, 20892-1908, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5759-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549366PMC
June 2019

Finding an Immunologic Beachhead in the Prostate Cancer Microenvironment.

J Natl Cancer Inst 2019 Mar;111(3):219-220

Genitourinary Malignancies Branch, NCI, CCR, NIH, Bethesda, MD.

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/advance-article/doi/10.1093/jn
Publisher Site
http://dx.doi.org/10.1093/jnci/djy145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657437PMC
March 2019

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.

J Immunother Cancer 2019 Jan 16;7(1):12. Epub 2019 Jan 16.

Genitourinary Malignancies Branch and Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0
Publisher Site
http://dx.doi.org/10.1186/s40425-018-0459-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335739PMC
January 2019

Vaccines as an Integral Component of Cancer Immunotherapy.

JAMA 2018 Dec;320(21):2195-2196

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2018.9511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538063PMC
December 2018

Product review: avelumab, an anti-PD-L1 antibody.

Hum Vaccin Immunother 2019 20;15(4):891-908. Epub 2018 Dec 20.

a Medical Oncology Service, Center for Cancer Research , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1
Publisher Site
http://dx.doi.org/10.1080/21645515.2018.1551671DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605872PMC
December 2018

Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.

J Immunother Cancer 2018 12 18;6(1):150. Epub 2018 Dec 18.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr., Rm. B2L312, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0
Publisher Site
http://dx.doi.org/10.1186/s40425-018-0473-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299503PMC
December 2018

M7824: A promising new strategy to combat cancer immune evasion.

Oncoscience 2018 Nov 22;5(11-12):269-270. Epub 2018 Aug 22.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://impactjournals.com/oncoscience/index.php?pii=451
Publisher Site
http://dx.doi.org/10.18632/oncoscience.451DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326736PMC
November 2018

Pembrolizumab: patient selection or immune intensification?

Nat Rev Urol 2018 Oct;15(10):593-594

Genitourinary Malignancies Branch, Centre for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-018-0076-zDOI Listing
October 2018

Avelumab: is it time to get excited?

Expert Rev Anticancer Ther 2018 09 2;18(9):815-821. Epub 2018 Jul 2.

b Department of Medicine , Replimune Group Inc , Woburn , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1493380DOI Listing
September 2018

Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.

J Immunother Cancer 2018 09 18;6(1):91. Epub 2018 Sep 18.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Dr., Room B2L312, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0409-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145343PMC
September 2018

Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).

Hum Pathol 2018 08 30;78:72-78. Epub 2018 Apr 30.

Laboratory of Tumor Immunology and Biology, CCR, NCI, NIH, Bethesda, MD 20892.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2018.04.013DOI Listing
August 2018

Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.

Expert Rev Vaccines 2018 08 22;17(8):697-705. Epub 2018 Aug 22.

a Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute , National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2018.1506332DOI Listing
August 2018

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.

J Immunother Cancer 2017 21;5:20. Epub 2017 Feb 21.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 8B09, Bethesda, MD USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0220-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320726PMC
June 2018

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.

Cancer 2018 05 22;124(9):2010-2017. Epub 2018 Feb 22.

Genitourinary Malignancies Branch, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31293DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947549PMC
May 2018

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

J Immunother Cancer 2018 05 14;6(1):35. Epub 2018 May 14.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0342-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950135PMC
May 2018

Combining immunotherapies for the treatment of prostate cancer.

Urol Oncol 2017 12;35(12):694-700

Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2017.09.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599516PMC
December 2017

Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot".

J Natl Cancer Inst 2017 12;109(12)

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx132DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279267PMC
December 2017

Immunotherapy of Prostate Cancer: Facts and Hopes.

Clin Cancer Res 2017 Nov 29;23(22):6764-6770. Epub 2017 Jun 29.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690854PMC
November 2017

Checkpoint and PARP inhibitors, for whom and when.

Oncotarget 2017 Nov 12;8(56):95036-95037. Epub 2017 Sep 12.

Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20852DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707002PMC
November 2017

Avelumab demonstrates promise in advanced NSCLC.

Oncotarget 2017 Nov 13;8(61):102767-102768. Epub 2017 Nov 13.

James L. Gulley: Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732688PMC
November 2017

Prostate cancer immunotherapy: the path forward.

Curr Opin Support Palliat Care 2017 Sep;11(3):225-230

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SPC.0000000000000278DOI Listing
September 2017

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).

Oncotarget 2017 Sep 8;8(43):75217-75231. Epub 2017 Sep 8.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20680DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650414PMC
September 2017

ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.

Int J Cancer 2017 08 19;141(3):583-593. Epub 2017 May 19.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.30767DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604238PMC
August 2017

Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy.

Nat Rev Urol 2017 Aug 23;14(8):455-456. Epub 2017 May 23.

Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive 13N240, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2017.75DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628252PMC
August 2017

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.

J Clin Oncol 2017 Jul 4;35(19):2117-2124. Epub 2017 Apr 4.

Andrea B. Apolo and James L. Gulley, National Institutes of Health, Bethesda, MD; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Ani Balmanoukian, The Angeles Clinic & Research Institute; Alain C. Mita, Cedars Sinai Medical Center, Los Angeles; Karen Kelly, University of California-Davis, Sacramento; Marko Srdanov, Dako North America, Carpinteria, CA; Manish R. Patel, Florida Cancer Specialists & Research Institute, Sarasota, FL; Ding Wang, Henry Ford Hospital, Detroit, MI; Anthony E. Mega, The Warren Alpert Medical School at Brown University; Howard Safran, The Miriam Hospital, Providence; Howard Safran, Newport Hospital, Newport, RI; Carolyn D. Britten, Medical University of South Carolina, Charleston, SC; Alain Ravaud, CHU de Bordeaux, Bordeaux, France; Thomas E. Stinchcombe, Duke University Medical Center, Durham, NC; Arnold B. Gelb and Kevin Chin, EMD Serono, Billerica, MA; and Michael Schlichting, Merck, Darmstadt, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.6795
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.6795DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493051PMC
July 2017

Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.

J Immunother Cancer 2017 07 18;5(1):55. Epub 2017 Jul 18.

Department of Medicine, Surgery and Immunology, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Pittsburgh, PA, 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0262-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514521PMC
July 2017

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.

Oncoimmunology 2017 13;6(10):e1349589. Epub 2017 Jul 13.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2017.1349589DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665067PMC
July 2017

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.

Lancet Oncol 2017 05 31;18(5):587-598. Epub 2017 Mar 31.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(17)30239-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387686PMC
May 2017

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.

J Natl Cancer Inst 2017 04;109(4)

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and The Brady Urological Institute, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw261DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441294PMC
April 2017

Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.

J Clin Oncol 2017 01 30;35(1):124-125. Epub 2016 Sep 30.

Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, New York, NY; James L. Gulley, National Cancer Institute, Bethesda, MD; and Cesar Pico-Navarro, Bavarian Nordic, Redwood City, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.7748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411419PMC
January 2017

Prospects for the future of prostate cancer vaccines.

Expert Rev Vaccines 2016 7;15(3):271-4. Epub 2015 Dec 7.

a Genitourinary Malignancies Branch , National Cancer Institute , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14760584.2015.1118348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6641856PMC
November 2016

Immunotherapy in genitourinary malignancies.

Curr Opin Urol 2016 11;26(6):501-7

aHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California bGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/co-urology/2016/11000/Immunothe
Web Search
http://dx.doi.org/10.1097/MOU.0000000000000331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129842PMC
November 2016

Developing immunotherapy strategies in the treatment of prostate cancer.

Asian J Urol 2016 Oct 30;3(4):278-285. Epub 2016 Aug 30.

Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajur.2016.08.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730831PMC
October 2016

Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.

Hum Vaccin Immunother 2016 09 2;12(9):2219-31. Epub 2016 May 2.

b Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21645515.2016.1175694DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027703PMC
September 2016

Radium-223 in prostate cancer: emitting the right signals.

Lancet Oncol 2016 09 26;17(9):1186-7. Epub 2016 Jul 26.

Genitourinary Malignancies Branch, Center for Cancer Research, NCI, NIH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30248-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681812PMC
September 2016

Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.

Cancer Immunol Res 2016 09 2;4(9):755-65. Epub 2016 Aug 2.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-16-0037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138028PMC
September 2016

Predicting clinical outcomes in chordoma patients receiving immunotherapy: a comparison between volumetric segmentation and RECIST.

BMC Cancer 2016 08 23;16(1):672. Epub 2016 Aug 23.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 13N208, Bethesda, MD, 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-016-2699-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995658PMC
August 2016

Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors.

Expert Opin Biol Ther 2016 07 8;16(7):895-901. Epub 2016 Apr 8.

a Genitourinary Malignancies Branch , Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/14712598.2016.11
Publisher Site
http://dx.doi.org/10.1517/14712598.2016.1170805DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599515PMC
July 2016

The evolving role of immunotherapy in prostate cancer.

Curr Opin Oncol 2016 May;28(3):232-40

aClinical Center, National Institutes of Health, Bethesda bGenitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000281DOI Listing
May 2016

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm.

Oncoimmunology 2016 Apr 10;5(4):e1107698. Epub 2015 Dec 10.

Barts Cancer Institute, Queen Mary University of London , London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2015.1107698DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839373PMC
April 2016

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types.

J Circ Biomark 2016 Jan-Dec;5. Epub 2016 Mar 10.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5772/62322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548330PMC
March 2016

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.

Cancer Immunol Res 2015 Nov 30;3(11):1248-56. Epub 2015 Jun 30.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636967PMC
November 2015

The impact of leukapheresis on immune-cell number and function in patients with advanced cancer.

Cancer Immunol Immunother 2015 Nov 5;64(11):1429-35. Epub 2015 Aug 5.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs00262-015-17
Web Search
http://link.springer.com/10.1007/s00262-015-1738-9
Publisher Site
http://dx.doi.org/10.1007/s00262-015-1738-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6596285PMC
November 2015

Adding fuel to the fire: immunogenic intensification.

Hum Vaccin Immunother 2014 ;10(11):3306-12

a Genitourinary Malignancies Branch; Medical Oncology Service; National Cancer Institute; National Institutes of Health ; Bethesda , MD USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/21645515.2014.973318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514022PMC
October 2015

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

Cancer Immunol Res 2015 Oct 26;3(10):1148-1157. Epub 2015 May 26.

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739754PMC
October 2015

ABO blood type correlates with survival on prostate cancer vaccine therapy.

Oncotarget 2015 Oct;6(31):32244-56

Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.4993DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741674PMC
October 2015

Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells.

J Immunol 2015 May 30;194(9):4215-21. Epub 2015 Mar 30.

Cancer and Inflammation Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1402004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4402268PMC
May 2015

Therapeutic cancer vaccines.

Adv Cancer Res 2014 ;121:67-124

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-800249-0.00002-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324585PMC
April 2015

Moving the goal posts in prostate cancer trials.

Lancet Oncol 2015 Mar 18;16(3):247-9. Epub 2015 Feb 18.

National Cancer Institute, National Institutes of Health, Center Drive, Bethesda, MD 20892, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)70071-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6632068PMC
March 2015

(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment.

J Natl Cancer Inst 2015 Jan 27;107(1):347. Epub 2014 Nov 27.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju347DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271077PMC
January 2015

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

Front Oncol 2014 12;4:351. Epub 2014 Dec 12.

Genitourinary Malignancies Branch, National Cancer Institute, National Institute of Health , Bethesda, MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2014.00351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264488PMC
January 2015

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer.

Transl Lung Cancer Res 2014 Dec;3(6):403-5

1 Thoracic and Gastrointestinal Oncology Branch, 2 Laboratory of Tumor Immunology and Biology and Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2014.09.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367666PMC
December 2014

Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.

Ther Adv Vaccines 2014 Sep;2(5):137-48

Chief, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, 12N226, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2051013614539478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144263PMC
September 2014

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients.

Oncoimmunology 2014 29;3:e28611. Epub 2014 Apr 29.

Laboratory of Tumor Immunology and Biology; National Cancer Institute; National Institutes of Health; Bethesda, MD USA ; Genitourinary Malignancies Branch; National Cancer Institute; National Institutes of Health; Bethesda, MD USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.28611DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091323PMC
April 2014